Roth MKM Maintains Buy on OptimizeRx, Lowers Price Target to $20
Portfolio Pulse from jenniferd'souza@benzinga.com
Roth MKM analyst Richard Baldry has maintained a 'Buy' rating on OptimizeRx (NASDAQ:OPRX) but lowered the price target from $31 to $20.
August 15, 2023 | 3:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
OptimizeRx's price target has been lowered from $31 to $20 by Roth MKM, although the 'Buy' rating is maintained.
The lowering of the price target by Roth MKM could potentially lead to a short-term decrease in OptimizeRx's stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100